Literature DB >> 23560418

The effect of bone marrow- and adipose tissue-derived mesenchymal stem cell transplantation on myocardial remodelling in the rat model of ischaemic heart failure.

Andrey A Karpov1, Yulia K Uspenskaya, Sarkis M Minasian, Maxim V Puzanov, Renata I Dmitrieva, Anna A Bilibina, Sergey V Anisimov, Michael M Galagudza.   

Abstract

This study aimed to investigate the effect of bone marrow- and adipose tissue-derived mesenchymal stem cell (BM-MSC and AD-MSC respectively) transplantation on left ventricular function and infarct area (IA) in the rat model of ischaemic heart failure. In anaesthetized Wistar rats, the left coronary artery (LCA) was occluded for 40 min with subsequent reperfusion for 7 days. Seven days following surgery, the animals with LCA occlusion/reperfusion were randomized into three groups: (i) Controls received intramyocardial injection of vehicle at three different locations within the peri-infarct zone, (ii) BM-MSC: cells were injected in the same way as in previous group (10(6) ), (iii) AD-MSC: using the same protocol as used in the BM-MSC group. In addition there was also a sham-treated group that had no injection. Two weeks following MSC transplantation, the hearts were isolated and perfused according to the Langendorff method followed by 30-min global ischaemia and 90-min reperfusion. After this IA was determined histologically. During Langendorff perfusion initial and postischaemic LV functions were the same in all groups although LV pressure at the 10th minute of reperfusion was higher in the AD-MSC group compared to controls. However, LV pressure during 30-min global ischaemia was significantly higher in BM-MSC as compared to controls and AD-MSC. The sham treated animals showed the same results as those seen with BM-MSC. Thus, BM-MSC transplantation, in contrast to transplantation of AD-MSC, resulted in better preservation of the LV ability to contract during ischaemia. Furthermore, IA was significantly smaller in BM-MSC group as compared to the controls and the AD-MSC groups. Thus this study has demonstrated that treatment with BM-MSC both ameliorates LV function and reduces histological scar size.
© 2013 The Authors. International Journal of Experimental Pathology © 2013 International Journal of Experimental Pathology.

Entities:  

Mesh:

Year:  2013        PMID: 23560418      PMCID: PMC3664961          DOI: 10.1111/iep.12017

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  31 in total

1.  Endoventricular porcine autologous myoblast transplantation can be successfully achieved with minor mechanical cell damage.

Authors:  Bénédicte Chazaud; Luc Hittinger; Corinne Sonnet; Stéphane Champagne; Philippe Le Corvoisier; Nicole Benhaiem-Sigaux; Thierry Unterseeh; Jinbo Su; Pascal Merlet; Alain Rahmouni; Jérôme Garot; Romain Gherardi; Emmanuel Teiger
Journal:  Cardiovasc Res       Date:  2003-05-01       Impact factor: 10.787

2.  Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials.

Authors:  Dongming Hou; Eyas Al-Shaykh Youssef; Todd J Brinton; Ping Zhang; Pamela Rogers; Erik T Price; Alan C Yeung; Brian H Johnstone; Paul G Yock; Keith L March
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

3.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

4.  The comparison of multilineage differentiation of bone marrow and adipose-derived mesenchymal stem cells.

Authors:  Xishan Zhu; Jing Du; Gang Liu
Journal:  Clin Lab       Date:  2012       Impact factor: 1.138

5.  Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction--comparison with nonischemic cardiomyopathy.

Authors:  Nobuyuki Shiba; Jun Watanabe; Tsuyoshi Shinozaki; Yoshito Koseki; Masahito Sakuma; Yutaka Kagaya; Kunio Shirato
Journal:  Circ J       Date:  2005-02       Impact factor: 2.993

6.  Bone marrow cells regenerate infarcted myocardium.

Authors:  D Orlic; J Kajstura; S Chimenti; I Jakoniuk; S M Anderson; B Li; J Pickel; R McKay; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Nature       Date:  2001-04-05       Impact factor: 49.962

7.  Idiotypic analysis of potential and available repertoires in the arsonate system.

Authors:  M Slaoui; O Leo; J Marvel; M Moser; J Hiernaux; J Urbain
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

8.  Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis.

Authors:  Noritoshi Nagaya; Takafumi Fujii; Takashi Iwase; Hajime Ohgushi; Takefumi Itoh; Masaaki Uematsu; Masakazu Yamagishi; Hidezo Mori; Kenji Kangawa; Soichiro Kitamura
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-29       Impact factor: 4.733

9.  A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction.

Authors:  Toby Freyman; Glenn Polin; Hashim Osman; Jody Crary; MinMin Lu; Lan Cheng; Maria Palasis; Robert L Wilensky
Journal:  Eur Heart J       Date:  2006-03-01       Impact factor: 29.983

10.  Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world.

Authors:  F Levi; F Lucchini; E Negri; C La Vecchia
Journal:  Heart       Date:  2002-08       Impact factor: 5.994

View more
  14 in total

Review 1.  Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells.

Authors:  Andrey A Karpov; Daria V Udalova; Michael G Pliss; Michael M Galagudza
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

2.  Non-inferiority of microencapsulated mesenchymal stem cells to free cells in cardiac repair after myocardial infarction: A rationale for using paracrine factor(s) instead of cells.

Authors:  Andrey A Karpov; Maxim V Puzanov; Dmitry Yu Ivkin; Marina V Krasnova; Nikita A Anikin; Pavel M Docshin; Olga M Moiseeva; Michael M Galagudza
Journal:  Int J Exp Pathol       Date:  2019-04-24       Impact factor: 1.925

Review 3.  Therapeutic application of adipose derived stem cells in acute myocardial infarction: lessons from animal models.

Authors:  B A Naaijkens; A van Dijk; O Kamp; P A J Krijnen; H W M Niessen; L J M Juffermans
Journal:  Stem Cell Rev Rep       Date:  2014-06       Impact factor: 5.739

4.  Functional properties of bone marrow derived multipotent mesenchymal stromal cells are altered in heart failure patients, and could be corrected by adjustment of expansion strategies.

Authors:  Renata I Dmitrieva; Alla V Revittser; Maria A Klukina; Yuri V Sviryaev; Ludmila S Korostovtseva; Anna A Kostareva; Andrey Yu Zaritskey; Evgeny V Shlyakhto
Journal:  Aging (Albany NY)       Date:  2015-01       Impact factor: 5.682

5.  Intra-renal delivery of mesenchymal stem cells attenuates myocardial injury after reversal of hypertension in porcine renovascular disease.

Authors:  Alfonso Eirin; Xiang-Yang Zhu; Christopher M Ferguson; Scott M Riester; Andre J van Wijnen; Amir Lerman; Lilach O Lerman
Journal:  Stem Cell Res Ther       Date:  2015-01-19       Impact factor: 6.832

6.  Bone marrow-derived mesenchymal stem cells rescue injured H9c2 cells via transferring intact mitochondria through tunneling nanotubes in an in vitro simulated ischemia/reperfusion model.

Authors:  Hui Han; Jinquan Hu; Qiang Yan; Jinzhou Zhu; Zhengbin Zhu; Yanjia Chen; Jiateng Sun; Ruiyan Zhang
Journal:  Mol Med Rep       Date:  2015-12-28       Impact factor: 2.952

Review 7.  Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy.

Authors:  Jorge Zorzopulos; Steven M Opal; Andrés Hernando-Insúa; Juan M Rodriguez; Fernanda Elías; Juan Fló; Ricardo A López; Norma A Chasseing; Victoria A Lux-Lantos; Maria F Coronel; Raul Franco; Alejandro D Montaner; David L Horn
Journal:  World J Stem Cells       Date:  2017-03-26       Impact factor: 5.326

8.  Comparative Study of Microtubule-associated Protein-2 and Glial Fibrillary Acidic Proteins during Neural Induction of Human Bone Marrow Mesenchymal Stem Cells and Adipose-Derived Stem Cells.

Authors:  Fatemeh Sadat Mostafavi; Shahnaz Razavi; Mohammad Mardani; Ebrahim Esfandiari; Hamid Zarkesh Esfahani; Mohammad Kazemi
Journal:  Int J Prev Med       Date:  2014-05

9.  Magnetic resonance imaging with superparamagnetic iron oxide fails to track the long-term fate of mesenchymal stem cells transplanted into heart.

Authors:  Ning Ma; Huaibing Cheng; Minjie Lu; Qiong Liu; Xiuyu Chen; Gang Yin; Hao Zhu; Lianfeng Zhang; Xianmin Meng; Yue Tang; Shihua Zhao
Journal:  Sci Rep       Date:  2015-03-12       Impact factor: 4.379

10.  Are They Really Stem Cells? Scrutinizing the Identity of Cells and the Quality of Reporting in the Use of Adipose Tissue-Derived Stem Cells.

Authors:  Ernesto Balolong; Soojung Lee; Judee Grace Nemeno; Jeong Ik Lee
Journal:  Stem Cells Int       Date:  2015-12-20       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.